Publications by authors named "R Schuit"
Assessment of fully quantitative and simplified methods for analysis of [Ga]Ga-FAPI-46 uptake in patients with pancreatobiliary cancer using LAFOV PET/CT.
Eur J Nucl Med Mol Imaging
January 2025
Article Synopsis
- The study aimed to validate simpler methods for measuring [Ga]Ga-FAPI-46 uptake by comparing them to comprehensive pharmacokinetic modeling.
- Ten patients with pancreatobiliary cancer participated in a 90-minute dynamic PET/CT scan, and various methods, including plasma-input tissue-compartment models, were used to assess the uptake of the compound in lesions.
- The results indicated that image-based target-to-whole blood ratio (TBR) and mean standardized uptake values (SUVmean) at 60-70 minutes post-injection are effective and reliable for quantifying [Ga]Ga-FAPI-46 uptake.
Article Synopsis
- This study looks at a new imaging tracer called [F]F-AraG, which helps scientists understand how cancer and the immune system interact, particularly in lung cancer patients.
- Researchers tested this tracer in 13 patients to figure out the best way to measure how much of it gets taken up by tumors over time.
- The results showed that the 2T3k model was the best for understanding how the tracer works, and two specific measurements (TBR and TPR) were very useful for comparing results across different time periods.
Background: Mutations in the epidermal growth factor receptor (EGFR) kinase domain are common in non-small cell lung cancer. Conventional tyrosine kinase inhibitors target the mutation site in the ATP binding pocket, thereby inhibiting the receptor's function. However, subsequent treatment resistance mutations in the ATP binding site are common.
View Article and Find Full Text PDFActivated Abelson non-receptor tyrosine kinase (c-Abl) plays a harmful role in neurodegenerative conditions such as Parkinson's disease (PD). Inhibition of c-Abl is reported to have a neuroprotective effect and be a promising therapeutic strategy for PD. We have previously identified a series of benzo[]thiazole derivatives as selective c-Abl inhibitors from which one compound showed high therapeutic potential.
View Article and Find Full Text PDFBrigatinib, a tyrosine kinase inhibitor (TKI) with specificity for gene rearranged anaplastic lymphoma kinase (ALK), such as the EML4-ALK, has shown a potential to inhibit mutated epidermal growth factor receptor (EGFR). In this study, -desmethyl brigatinib was successfully synthesized as a precursor in five steps. Radiolabeling with [C]methyl iodide produced [-C]brigatinib in a 10 ± 2% radiochemical yield, 91 ± 17 GBq/μmol molar activity, and ≥95% radiochemical purity in 49 ± 4 min.
View Article and Find Full Text PDF